New insights into progressive multifocal leukoencephalopathy.

Area of Science:

• Neuroscience
• Virology
• Immunology

Background:

• Progressive multifocal leukoencephalopathy (PML) is a fatal demyelinating disease of the central nervous system (CNS) affecting immunosuppressed individuals.
• It is caused by the reactivation of the JC polyomavirus (JCV), leading to oligodendrocyte infection and lysis.
• This review focuses on recent clinical, pathological, and etiological advancements in PML.

Purpose of the Study:

• To review recent developments in the clinical and pathological presentations of PML.
• To discuss advances in understanding JC virus biology and pathogenesis.
• To explore implications for patient management and novel therapeutic strategies.

Main Methods:

• Review of recent literature on PML clinical and pathological findings.
• Analysis of advances in JC virus biology and pathogenesis.
• Evaluation of the role of cellular immune responses in PML.

Main Results:

• Highly active antiretroviral therapy (HAART) has reduced PML mortality in HIV-infected individuals from 90% to approximately 50% due to immune system recovery.
• An increasing number of PML patients test JC virus-negative in cerebrospinal fluid via PCR, necessitating revised terminology.
• Inflammatory PML forms are more common, associated with a robust JC virus-specific CD8 cytotoxic T lymphocyte response that aids in preventing disease progression.

Conclusions:

• Understanding JCV biology illuminates PML pathogenesis and its potential role in cerebellar atrophy in HIV patients.
• Cellular immune responses against JCV have direct implications for managing PML and developing immunotherapies.
• A non-human primate animal model for PML will accelerate the development of novel therapeutic strategies.